Privium Fund Management (Uk) LTD Aurinia Pharmaceuticals Inc. Transaction History

Privium Fund Management (Uk) LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$7.13 - $9.49 $483,791 - $643,924	67,853 New	67,853 $609,000
Q2 2022 Jul 28, 2022	BUY	$8.95 - $12.8 $33,929 - $48,524	3,791 Added 15.04%	29,000 $291,000
Q1 2022 May 10, 2022	BUY	$10.05 - $22.48 $52,350 - $117,098	5,209 Added 26.05%	25,209 $312,000
Q4 2021 Mar 25, 2022	BUY	$17.78 - $33.08 $355,600 - $661,600	20,000 New	20,000 $460,000
Q4 2021 Feb 08, 2022	SELL	$17.78 - $33.08 $355,600 - $661,600	-20,000 Closed	0 $0
Q3 2021 Nov 05, 2021	BUY	$10.93 - $23.55 $218,600 - $471,000	20,000 New	20,000 $443,000

209

58.7M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.15B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Privium Fund Management (Uk) LTD, based on Form 13F filings with the SEC.

Stay updated on Privium Fund Management (Uk) LTD with notifications on news.